Druggability & Clinical Context
Druggability
Medium
Score: 0.52
Target Class
Structural Protein
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
3
Known Drugs:
3
Approved:
0
In Clinical Trials:
0
Drug Pipeline (3 compounds)
Therapeutic Areas:Alzheimer's disease Neuroinflammation Neurodegeneration (general) Traumatic brain injury Multiple sclerosis Frontotemporal dementia Parkinson's disease
Druggability Rationale: GFAP is a structural cytoskeletal protein with inherently low druggability (0.25 score) and lacks direct binding pockets suitable for small-molecule inhibition. Therapeutic intervention requires indirect modulation through upstream inflammatory pathways (NF-κB, JAK-STAT) rather than direct GFAP targeting, making it more suitable as a biomarker readout for drug efficacy than as a primary drug target.
Mechanism: Biomarker readout — GFAP levels reflect astrocyte reactivity; modulating upstream pathways (e.g., NF-κB, JAK-STAT) reduces GFAP expression
Drug Pipeline (3 compounds)
Known Drugs:UCB0599 (Minzasolmin) (Phase II)
Lecanemab (Approved)
Donanemab (Approved)
Structural Data:PDB (3) ✓AlphaFold ✓Cryo-EM —
Binding Pocket Analysis:GFAP lacks a conventional ligand-binding pocket as a structural protein; therapeutic approaches rely on antibody-based biomarker detection or indirect modulation via inflammatory signaling epitopes. No ATP-binding or allosteric small-molecule binding sites have been characterized, limiting traditional drug development approaches.
Selectivity & Safety Considerations
GFAP selectivity is not a traditional concern since it is astrocyte-specific; however, peripheral astrocyte activation versus CNS astrocytes presents a challenge for biomarker interpretation. Off-target risk is minimal for GFAP-targeting agents, but upstream pathway modulators (NF-κB, JAK-STAT inhibitors) will have broad systemic effects across immune and other cell types.
Clinical Trials (8)
Relevant trials from ClinicalTrials.gov
By Phase
NA: 1 · PHASE2: 1 · PHASE3: 1 · PHASE4: 2 · Unknown: 3
Unknown
NCT06741553
n=120
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Interventions: Lecanemab 10 mg/kg
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang Uni | Started: 2024-06-28
Unknown
NCT06322667
n=5000
Alzheimer's Disease
Interventions: No Intervention
Sponsor: Eisai Co., Ltd. | Started: 2024-02-14
Unknown
NCT06566170
n=6250
Alzheimer Disease
Interventions: Donanemab, Usual Care
Sponsor: Eli Lilly and Company | Started: 2024-10-07
PHASE4
NCT06911944
n=60
Down Syndrome (DS), Down Syndrome (Trisomy 21), Alzheimer Disease
Interventions: Donanemab, Placebo
Sponsor: Michael Rafii, MD, PhD | Started: 2026-08-01
PHASE2
NCT06996730
n=240
Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease, Alzheimers Disease
Interventions: Donanemab, RG6289, Donanemab placebo
Sponsor: Banner Health | Started: 2026-01-15
NA
NCT07456462
n=50
Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI)
Interventions: MRI assessment and blood sample collecti
Sponsor: IRCCS San Raffaele | Started: 2026-05-01
PHASE4
NCT07034222
n=80
Alzheimer's Disease(AD)
Interventions: Administer Leqemi 10 mg/kg, every two we
Sponsor: Ruijin Hospital | Started: 2024-02-01
PHASE3
NCT05738486
n=1175
Alzheimer's Disease, Dementia, Brain Diseases
Interventions: Donanemab, Placebo, Dexamethasone
Sponsor: Eli Lilly and Company | Started: 2023-02-28